Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Bonus Story from MarketBeat 2 Small-Cap Biotechs That Could Reward Patient InvestorsBy Chris Markoch. Article Posted: 12/12/2025. 
What You Need to Know - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is essential. Most of these companies remain in the clinical stage and have no commercially available drugs or therapeutics. That also means negative earnings and little to no revenue. Success often hinges on the outcome of a single clinical-stage program, and even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically attract the analyst coverage that brings institutional investment. A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his "One Ticker" approach works — and how readers can access the full service for a year at a steep discount. Watch the brief demo here Still, getting in on one of these medical stocks early and having it succeed can produce outsized returns. Investors can see 3x, 5x, or even 10x gains if a development program breaks through. Others will never pan out, which is why many investors who trade penny stocks spread a lump sum across a number of biotech names. If it is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risk but also offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert – the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results from a feasibility study in October. That program, however, remains years away from potential commercial approval. Risks are substantial. ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue remains limited. The company disclosed “Going Concern” language in its Sept. 26 SEC filing and has since filed a $150 million mixed shelf offering. That financing should help keep MYNZ above $1 and avoid a delisting notice for now. Mainz Biomed is racing to generate enough revenue to make a material impact. If it succeeds, even a relatively small investment could produce a sizable return, but the path is uncertain and requires patience. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that pursues a potentially disruptive antiviral approach, but it carries the financial risks typical of speculative small caps. The company is developing a novel class of antiviral therapies using its proprietary “nanoviricide” platform. These candidates are engineered to mimic human cell surfaces and lure viruses into binding with them, neutralizing the pathogens before they can infect real cells. If validated in human trials, this would represent a fundamentally different method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data demonstrating strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on external capital to continue development. Recent filings indicate limited cash on hand, and investors should expect the possibility of future dilution. That said, if even one candidate advances successfully into clinical development and eventually gains approval, the valuation upside could be substantial. For investors with a long time horizon and a high tolerance for risk, NNVC represents a true moonshot in the antiviral space.
| 
